Efalizumab

From WikiMD's Wellnesspedia


Information about Efalizumab[edit source]

Efalizumab is a humanized monoclonal antibody to human CD11a subunit of the lymphocyte function-associated antigen 1, which acts as an immunosuppressant agent blocking lymphocyte activation and was formerly used to treat severe plaque psoriasis. 


Liver safety of Efalizumab[edit source]

Efalizumab has been linked to rare instances of idiosyncratic acute liver injury and may be a rare cause of reactivation of hepatitis B.

== Mechanism of action of Efalizumab ==  Efalizumab (ef” al iz’ ue mab) is a recombinant, humanized monoclonal antibody to CD11a, a subunit of the lymphocyte function-associated antigen 1 (LFA-1), which is present on lymphocytes and causes activation and proliferation of lymphocytes.  Blocking of CD11a inhibits lymphocyte activation and decreases migration of lymphocytes to sites of inflammation.  Efalizumab has been shown to have potent immunosuppressive activity and to lower lymphocyte counts and improve autoimmune conditions.  In controlled studies, efalizumab was shown to be effective in inducing clinical responses in 20% to 30% of patients with severe psoriasis. 

FDA approval information for Efalizumab[edit source]

Efalizumab was approved for use in the United States in 2005 as therapy for severe plaque psoriasis, but was withdrawn in 2009 because of several instances of progressive multifocal leukoencephalopathy (PMLE), a severe neurological condition which is believed to be due to reactivation of the JC virus in neural cells. 

Brand name for Efalizumab[edit source]

Efalizumab was previously available in 125 mg single use vials under the brand name Raptiva. 

Dosage and administration for Efalizumab[edit source]

The recommended initial dose was 0.7 mg/kg subcutaneously, followed by weekly doses of 1 mg/kg, with maximum single dose of 200 mg. 

Side effects of Efalizumab[edit source]

Common side effects included headache, fatigue, fever, muscle and back aches, nausea, acne and hypersensitivity reactions.  Efalizumab is also capable of causing immune suppression, resulting in an increased susceptibility to opportunistic infections.

Antipsoriasis agents[edit source]

Monoclonal Antibodies IL-17A Antagonists

Tumor Necrosis Factor Antagonists

Other

Efalizumab Resources

Find a healthcare provider anywhere in the world quickly and easily!

Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.


Contributors: Prab R. Tumpati, MD